Tolvaptan

證據等級: L5

預測適應症: 10 個

Tolvaptan: From Unspecified Original Indication to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)

One-Sentence Summary

The original approved indication of Tolvaptan is not specified in the current evidence pack. The TxGNN model predicts it may be effective for Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease), with 0 registered clinical trials but 20 supporting publications, including two pivotal Phase 3 randomized controlled trials (NEJM, 2012 and 2017), currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (no `original_indications` or Taiwan license data available)
Predicted New Indication	Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
TxGNN Prediction Score	99.99% (0.99987)
Evidence Level	L1 (≥2 completed Phase 3 RCTs identified in literature)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the drug-level fields for Tolvaptan (original_moa: [Data Gap]). However, the literature included in this evidence pack consistently identifies Tolvaptan as a vasopressin V2-receptor antagonist (e.g., PMID 23121377, PMID 16672911). Preclinical and clinical studies cited in the literature indicate that V2-receptor blockade inhibits renal cyst growth and slows the decline of kidney function, which is the mechanistic basis for its use in cystic kidney disease.

The predicted new indication — polycystic kidney disease 3 with or without polycystic liver disease — is mechanistically and clinically closely related to Autosomal Dominant Polycystic Kidney Disease (ADPKD), the condition studied in the pivotal trials referenced here (TEMPO 3:4, PMID 23121377; REPRISE, PMID 29105594). Multiple review articles and consensus statements in the evidence pack (PMID 35134221, PMID 40126492) confirm that Tolvaptan’s cyst-growth-inhibiting mechanism is directly applicable to this disease group, including its hepatic (polycystic liver disease) manifestations (PMID 35487607, PMID 29175241).

Given that the mechanistic rationale (V2-receptor antagonism → reduced cyst growth) is well documented across independent literature sources, and that two large Phase 3 RCTs directly support efficacy in a closely related/overlapping disease phenotype, this TxGNN prediction is biologically and clinically well grounded — even though the evidence pack itself does not register formal clinical_trials entries for this exact disease term.

Clinical Trial Evidence

Currently no related clinical trials registered.

(Note: Two pivotal Phase 3 RCTs for the closely related ADPKD phenotype are documented in the Literature Evidence section below, but are not indexed as structured clinical_trials entries in this evidence pack.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23121377	2012	RCT (Phase 3, TEMPO 3:4)	New England Journal of Medicine	Tolvaptan (V2-receptor antagonist) slowed the increase in total kidney volume and decline in eGFR in ADPKD patients
29105594	2017	RCT (Phase 3, REPRISE)	New England Journal of Medicine	Confirmed efficacy and safety of Tolvaptan in later-stage ADPKD (lower baseline eGFR population)
37150675	2023	Systematic Review / Meta-analysis	Nefrologia	Pooled analysis confirms efficacy and safety of Tolvaptan in delaying ADPKD progression to ESRD
39356039	2024	Cochrane Systematic Review	Cochrane Database of Systematic Reviews	Evaluates disease-modifying agents, including Tolvaptan, for preventing ADPKD progression
35134221	2022	Consensus Statement	Nephrology Dialysis Transplantation	ERA/European Rare Kidney Disease Network consensus on evidence-based Tolvaptan initiation in ADPKD
38091246	2024	RCT (Pediatric)	Pediatric Nephrology	Tolvaptan safety and pharmacodynamics evaluated in pediatric ADPKD patients (NCT02964273)
40126492	2025	Review	JAMA	Comprehensive review of ADPKD confirming Tolvaptan as the primary disease-modifying therapy
35487607	2022	Review	Clinics in Liver Disease	Tolvaptan slows deterioration of renal function and cyst growth in ADPKD with hepatic involvement
35328738	2022	Review	International Journal of Molecular Sciences	Reviews cystogenesis pathophysiology and treatment advances, including Tolvaptan’s role
40726372	2025	Review	Current Opinion in Nephrology and Hypertension	Notes Tolvaptan as the only FDA-approved disease-modifying ADPKD therapy; reviews emerging alternatives

US Market Information

Currently not marketed in the target jurisdiction; no NDA/license records are available in the evidence pack (total_licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

(Note: key_warnings, contraindications, and DDI data are flagged as a Blocking data gap — DG001 — pending TFDA label acquisition.)

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic and literature evidence for this indication is strong (L1, supported by two pivotal Phase 3 RCTs and a Cochrane systematic review), but a Blocking data gap (DG001) on TFDA warnings and contraindications currently prevents entry into the S1 safety initial evaluation stage. The drug is also not currently marketed in the target jurisdiction, so regulatory pathway feasibility is unconfirmed.

To proceed, the following is needed:

TFDA (or equivalent local regulator) approved label with warnings/contraindications (DG001, remediation: download and parse official label PDF)
Confirmed drug mechanism of action from DrugBank API (DG002)
Confirmation of Tolvaptan’s actual original approved indication(s) and any existing local market authorization
Formal drug-drug interaction (DDI) review, currently returning no data (query_status: not_found)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.